Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 769640
                    [Title] => Hepatitis B outbreak affects diabetics in long-term care
                    [Summary] => 
At least 17 hepatitis B virus infection outbreaks have occurred since 1996 in diabetes patients in long-term care settings, including assisted living facilities, according to a Centers for Disease Control and Prevention scientist.
                    [DatePublished] => 2012-01-22 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 648251
                    [Title] => Chronic hepatitis B
                    [Summary] => 
Chronic hepatitis B virus (HBV) infection remains a major public health risk.
                    [DatePublished] => 2011-01-16 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 413586
                    [Title] => Screening for HCC in high-risk patients key to reducing mortality
                    [Summary] => Enhanced surveillance of at-risk population is critical for the early identification and successful treatment of hepatocellular ...
                    [DatePublished] => 2008-11-09 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 338972
                    [Title] => Hepatitis B treatment strategies
                    [Summary] => Hepatitis B  virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis B (CHB) should be based  on rapidly emerging data and knowledge of the clinical consensus regarding CHB. There is no way to predict reliably which patients will experience the sequelae of CHB – complications of cirrhosis and hepatocellular carcinoma (HCC) – or time-to-onset of these clinical endpoints.
                    [DatePublished] => 2006-05-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 299580
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Conclusion)
In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts of the Nile delta. Epidemiologic studies have traced the source  of HCV infection to the large scale treatment campaigns against schistosomal infestation conducted between 1920 and 1970.
                    [DatePublished] => 2005-10-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 298429
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Continuation)

In the United States population, the cumulative life-time risk (CR) of liver cancer (hepatocellular carcinoma and intrahepatic bile duct carcinomas) is 0.88 percent in men and 0.42 percent in women, which is similar to that of esophageal cancer (CR=0.77 percent in men and 0.26 percent in women) or cancers of the larynx (CR=0.69 percent in men and 0.l7 percent in women).
                    [DatePublished] => 2005-09-25 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 294946
                    [Title] => Prevention of hepatitis B virus-related liver cancer  (Hepatocellular carcinoma)
                    [Summary] => The most effective means of preventing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is to prevent HBV infection via global vaccination of infants. Universal vaccination of newborns has been shown to significantly reduce the incidence of HCC among Taiwanese children. Among HBV carriers, the incidence of HCC was significantly higher in those who were hepatitis B e antigen positive, suggesting that antiviral therapy that results in viral clearance or sustained suppression of HBV replication should reduce the incidence of HCC.
                    [DatePublished] => 2005-09-04 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 274225
                    [Title] => 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without  booster doses in children
                    [Summary] => The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant  vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited.
                    [DatePublished] => 2005-04-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

HBV

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 769640
                    [Title] => Hepatitis B outbreak affects diabetics in long-term care
                    [Summary] => 
At least 17 hepatitis B virus infection outbreaks have occurred since 1996 in diabetes patients in long-term care settings, including assisted living facilities, according to a Centers for Disease Control and Prevention scientist.
                    [DatePublished] => 2012-01-22 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 648251
                    [Title] => Chronic hepatitis B
                    [Summary] => 
Chronic hepatitis B virus (HBV) infection remains a major public health risk.
                    [DatePublished] => 2011-01-16 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 413586
                    [Title] => Screening for HCC in high-risk patients key to reducing mortality
                    [Summary] => Enhanced surveillance of at-risk population is critical for the early identification and successful treatment of hepatocellular ...
                    [DatePublished] => 2008-11-09 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 338972
                    [Title] => Hepatitis B treatment strategies
                    [Summary] => Hepatitis B  virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis B (CHB) should be based  on rapidly emerging data and knowledge of the clinical consensus regarding CHB. There is no way to predict reliably which patients will experience the sequelae of CHB – complications of cirrhosis and hepatocellular carcinoma (HCC) – or time-to-onset of these clinical endpoints.
                    [DatePublished] => 2006-05-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 299580
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Conclusion)
In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts of the Nile delta. Epidemiologic studies have traced the source  of HCV infection to the large scale treatment campaigns against schistosomal infestation conducted between 1920 and 1970.
                    [DatePublished] => 2005-10-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 298429
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Continuation)

In the United States population, the cumulative life-time risk (CR) of liver cancer (hepatocellular carcinoma and intrahepatic bile duct carcinomas) is 0.88 percent in men and 0.42 percent in women, which is similar to that of esophageal cancer (CR=0.77 percent in men and 0.26 percent in women) or cancers of the larynx (CR=0.69 percent in men and 0.l7 percent in women).
                    [DatePublished] => 2005-09-25 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 294946
                    [Title] => Prevention of hepatitis B virus-related liver cancer  (Hepatocellular carcinoma)
                    [Summary] => The most effective means of preventing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is to prevent HBV infection via global vaccination of infants. Universal vaccination of newborns has been shown to significantly reduce the incidence of HCC among Taiwanese children. Among HBV carriers, the incidence of HCC was significantly higher in those who were hepatitis B e antigen positive, suggesting that antiviral therapy that results in viral clearance or sustained suppression of HBV replication should reduce the incidence of HCC.
                    [DatePublished] => 2005-09-04 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 274225
                    [Title] => 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without  booster doses in children
                    [Summary] => The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant  vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited.
                    [DatePublished] => 2005-04-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Hepatitis B outbreak affects diabetics in long-term care

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | January 22, 2012 - 12:00am

At least 17 hepatitis B virus infection outbreaks have occurred since 1996 in diabetes patients in long-term care settings, including assisted living facilities, according to a Centers for Disease Control and Prevention...

Opinion

Chronic hepatitis B

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | January 16, 2011 - 12:00am

Chronic hepatitis B virus (HBV) infection remains a major public health risk.

Opinion

Screening for HCC in high-risk patients key to reducing mortality

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | November 9, 2008 - 12:00am

Enhanced surveillance of at-risk population is critical for the early identification and successful treatment of hepatocellular ...

Opinion

Hepatitis B treatment strategies

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 28, 2006 - 12:00am

Hepatitis B virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis...

Opinion

Primary liver cancer: Worldwide incidence and trends

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | October 2, 2005 - 12:00am

(Conclusion) In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts...

Opinion

Primary liver cancer: Worldwide incidence and trends

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 25, 2005 - 12:00am

(Continuation) In the United States population, the cumulative life-time risk (CR) of liver cancer (hepatocellular carcinoma and intrahepatic bile duct carcinomas) is 0.88 percent in men and 0.42 percent in women,...

Opinion

Prevention of hepatitis B virus-related liver cancer (Hepatocellular carcinoma)

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 4, 2005 - 12:00am

The most effective means of preventing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is to prevent HBV infection via global vaccination of infants. Universal vaccination of newborns has been shown...

Opinion

18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | April 17, 2005 - 12:00am

The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18...

Opinion